CytomX surges on upcoming data for Amgen-partnered cancer drug

seekingalpha05-01

Shares of CytomX Therapeutics (NASDAQ:CTMX) climbed in the morning hours on Wednesday after the cancer drug developer fast-tracked an early-stage readout from its experimental bispecific antibody, CX-...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2432506729?lang=en_US&edition=fundamental","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1248262649/image_1248262649.jpg","is_english":true,"pubTime":"2024-05-01 22:42","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2432506729","market":"sg","top_or_hot":-1,"title":"CytomX surges on upcoming data for Amgen-partnered cancer drug","media":"seekingalpha","content":"<div>\n<p>Shares of CytomX Therapeutics (NASDAQ:CTMX) climbed in the morning hours on Wednesday after the cancer drug developer fast-tracked an early-stage readout from its experimental bispecific antibody, CX-...</p>\n\n<a href=\"https://seekingalpha.com/news/4097393-cytomx-stock-rises-upcoming-data-amgen-partnered-drug\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CytomX surges on upcoming data for Amgen-partnered cancer drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCytomX surges on upcoming data for Amgen-partnered cancer drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-05-01 22:42 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4097393-cytomx-stock-rises-upcoming-data-amgen-partnered-drug><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of CytomX Therapeutics (NASDAQ:CTMX) climbed in the morning hours on Wednesday after the cancer drug developer fast-tracked an early-stage readout from its experimental bispecific antibody, CX-...</p>\n\n<a href=\"https://seekingalpha.com/news/4097393-cytomx-stock-rises-upcoming-data-amgen-partnered-drug\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SG9999001440.SGD","symbol_name":"United Global Dividend Equity Fund A SGD Dist","start_time":0,"source_url":"https://seekingalpha.com/news/4097393-cytomx-stock-rises-upcoming-data-amgen-partnered-drug","article_id":"2432506729","we_media_id":null,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1248262649/image_1248262649.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2432506729","pubTimestamp":1714574576,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"Shares of CytomX Therapeutics  climbed in the morning hours on Wednesday after the cancer drug developer fast-tracked an early-stage readout from its experimental bispecific antibody, CX-904, developed in partnership with Amgen . The San Francisco, California-based biotech said that alongside its Q1 2024 financials expected on May 8 after the market close, the company would also release initial Phase 1a data for CX-904 from an ongoing dose escalation study.  CX-904 is currently undergoing a Phase 1 trial in certain patients with solid tumors, and in March, the company said its early Phase 1a results would be available in H2 2024. In 2017, Amgen  partnered with CytomX  to jointly develop and commercialize T-cell-engaging, EGFR-targeting bispecific therapeutics such as CX-904.","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","PSQ":"纳指反向ETF","BK4581":"高盛持仓","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","LU2242652126.USD":"FIDELITY FUNDS GLOBAL DIVIDENDS PLUS \"A\" (USD) INC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","QQQ":"纳指100ETF","QLD":"纳指两倍做多ETF","TQQQ":"纳指三倍做多ETF","LU0122379950.USD":"贝莱德世界健康科学A2","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU2242646821.SGD":"Fidelity Global Dividend Plus A-MINCOME(G)-SGD",".IXIC":"NASDAQ Composite","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","BK4585":"ETF&股票定投概念","AMGN":"安进","SQQQ":"纳指三倍做空ETF","BK4534":"瑞士信贷持仓","BK4139":"生物科技","LU0058720904.USD":"联博国际健康护理基金A","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4566":"资本集团","BK4588":"碎股","QID":"纳指两倍做空ETF","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","CTMX":"CytomX"},"translate_title":"CytomX因安进合作抗癌药物即将发布的数据而激增","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AMGN":1,"CTMX":1,".IXIC":0.75,"TQQQ":0.6,"PSQ":0.6,"QID":0.6,"QLD":0.6,"QQQ":0.6,"SQQQ":0.6,"NQmain":0.6,"MNQmain":0.6},"content_text":"Shares of CytomX Therapeutics (NASDAQ:CTMX) climbed in the morning hours on Wednesday after the cancer drug developer fast-tracked an early-stage readout from its experimental bispecific antibody, CX-904, developed in partnership with Amgen (NASDAQ:AMGN). The San Francisco, California-based biotech said that alongside its Q1 2024 financials expected on May 8 after the market close, the company would also release initial Phase 1a data for CX-904 from an ongoing dose escalation study.  CX-904 is currently undergoing a Phase 1 trial in certain patients with solid tumors, and in March, the company said its early Phase 1a results would be available in H2 2024. In 2017, Amgen (AMGN) partnered with CytomX (CTMX) to jointly develop and commercialize T-cell-engaging, EGFR-targeting bispecific therapeutics such as CX-904.","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2432506729"}